Market Cap | ₹17,195Cr |
ROE | 18.81% |
P/E Ratio(TTM) | 30.43 |
EPS(TTM) | 74.35 |
P/B Ratio | 6.03 |
Dividend Yield | 0.24% |
Industry P/E | 35.19 |
Book Value | 375.01 |
Debt to Equity | 0.00 |
Face Value | 2 |
Parent Organisation | Caplin Point Laboratories Limited |
Managing Director | Dr. Sridhar Ganesan |
NSE Symbol | CAPLIPOINT |
COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
---|---|---|---|---|
Torrent Pharmaceuticals | NA (0.00%) | 61.10 | ||
Gland Pharma | NA (0.00%) | 42.27 | ||
Ajanta Pharma | NA (0.00%) | 33.99 | ||
Eris Lifesciences | NA (0.00%) | 57.15 |